HOME >> BIOLOGY >> NEWS
FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable

table HIV, compared to 60 to 70 percent of 82 subjects who received MK-0518 without FUZEON. FUZEON usage was associated with dramatically increased response rates in the study by approximately 50 percent.

Compliment new treatment guidelines

These findings are consistent with the recently updated HIV treatment guidelines, which emphasise undetectability as the goal of therapy in treatment-experienced patients, as well as the need to initiate multiple active anti-HIV agents simultaneously in order to achieve this goal.3-5 Recent clinical trials have convinced the authors of the guidelines that undetectable viral load should be the goal for all treatment-experienced patients. These trials, including POWER and RESIST, confirm the efficacy of the new drugs darunavir and tipranavir and emphasise that FUZEON should be the cornerstone to achieve undetectable levels of virus for treatment-experienced patients.


'"/>

Contact: Alexander Watson
alexander.watson@ketchum.com
44-771-267-5990
Ketchum
5-Oct-2006


Page: 1 2

Related biology news :

1. Providence health system shows investigational osteoporosis therapy increases bone mineral density
2. Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. Cooperative science program yields results
5. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
6. Smelling for first time results from knowing abnormalities in congenital loss of smell
7. BDSI announces positive phase III clinical trial results
8. Scientists meet to review Envisat results after 5 years of operations
9. Environment and exercise may affect research results, UA study shows
10. Preliminary results of largest scan of autism DNA information
11. Human trial results show excellent safety data, from Geovaxs DNA/MVA AIDS vaccines

Post Your Comments:
(Date:5/17/2013)... (Intelligent Cargo in Efficient and Sustainable Global Logistics Operations) ... improvement in the efficiency of intermodal loading systems and ... It comprises 29 European organisations with experience in the ... a budget totalling 17,000,000 and a duration of three ... specify and develop the semantic components and ontologies shared ...
(Date:5/17/2013)... LEMONT, Ill. An international team ... internal structure and cell movement inside a living frog ... showcases a new method to advance biological research and ... at Northwestern University and the Karlsruher Institut fr Technologie ... at the U.S. Department of Energy,s Argonne National Laboratory, ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
(Date:5/20/2013)... Maryland (PRWEB) May 20, 2013 In ... in the field of biotoxin related illnesses , announced ... the country able to advance his protocol for treating ... Patel became the third physician to achieve certification in ... Certified Physicians, able to practice the Shoemaker Protocol in ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Dr. Sparano ... and Women’s Health at the Albert Einstein College of ... at the Montefiore Medical Center. He is also ... Center and leads the Einstein Breast Cancer Working Group, ... translational breast cancer research. He also serves as Vice ...
(Date:5/17/2013)... May 17, 2013 The new Public-Private ... at the association’s recent annual meeting drew praise ... Vice-President Neelie Kroes, who called the action “a huge ... a stimulant to European innovation.” , The Board of ... the new Photonics PPP at its 29 April meeting ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
Breaking Biology Technology:Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
Cached News: